

Manuela Monti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10194600/publications.pdf>

Version: 2024-02-01

34
papers

763
citations

687363

13
h-index

526287

27
g-index

39
all docs

39
docs citations

39
times ranked

983
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Approach for a Safe and Reproducible Seeds Positioning for Diffusing Alpha-Emitters Radiation Therapy of Squamous Cell Skin Cancer: A Feasibility Study. <i>Cancers</i> , 2022, 14, 240.	3.7	4
2	Theragnostic in neuroendocrine tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.7	2
3	Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials. <i>Molecules</i> , 2022, 27, 4143.	3.8	7
4	177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 152-160.	6.4	20
5	How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment Tool. <i>JCO Oncology Practice</i> , 2021, 17, e68-e76.	2.9	3
6	Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3260-3267.	6.4	29
7	Clinical research and burnout syndrome in Italy â€œ only a physiciansâ€™ affair?. <i>Trials</i> , 2021, 22, 205.	1.6	4
8	[18F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue. <i>Pharmaceuticals</i> , 2021, 14, 599.	3.8	3
9	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	6.4	13
10	Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. <i>European Journal of Radiology</i> , 2021, 141, 109821.	2.6	19
11	68Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. <i>Biomedicines</i> , 2020, 8, 536.	3.2	11
12	PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 689.	1.6	7
13	Hydroxychloroquine as Prophylaxis for COVID-19: A Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 605185.	3.5	10
14	Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3008-3017.	6.4	37
15	Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. <i>Radiation Oncology</i> , 2019, 14, 112.	2.7	16
16	Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 449-457.	0.9	27
17	Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol. <i>Molecules</i> , 2019, 24, 621.	3.8	34
18	Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3020-3020.	1.6	3

#	ARTICLE	IF	CITATIONS
19	New requirements for phase I trials: a challenge for Italian clinical research. <i>Tumori</i> , 2018, 104, 15-21.	1.1	5
20	Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 863-871.	2.3	14
21	Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). <i>Supportive Care in Cancer</i> , 2017, 25, 111-117.	2.2	8
22	Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with ¹⁷⁷ Lu-D OTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 490-499.	6.4	95
23	Peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and ¹⁸ F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1040-1046.	6.4	77
24	A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 600-600.	1.6	1
25	¹¹¹ In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer. <i>Nuclear Medicine Communications</i> , 2015, 36, 135-142.	1.1	1
26	Feasibility and utility of re-treatment with ¹⁷⁷ Lu-DOTATATE in GEP-NENs relapsed after treatment with ⁹⁰ Y-DOTATOC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1955-1963.	6.4	62
27	Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and ¹⁸ F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2015, 14, 721-727.	1.9	14
28	Metronomic capecitabine in gastroenteropancreatic neuroendocrine tumors: a suitable regimen and review of the literature. <i>OncoTargets and Therapy</i> , 2014, 7, 1919.	2.0	9
29	¹⁷⁷ Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1845-1851.	6.4	103
30	Treatment with the Radiolabelled Somatostatin Analog ¹⁷⁷Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2013, 97, 347-354.	2.5	104
31	Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Tj ETQq1 1 0.784314 mgBT /Ovs		
32	Innovative sequence of docetaxelâgemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. <i>Lung Cancer</i> , 2005, 47, 261-267.	2.0	4
33	Doxorubicin, Paclitaxel and Gemcitabine: a Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer. <i>Journal of Chemotherapy</i> , 2003, 15, 488-494.	1.5	6
34	Docetaxel Followed by Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer: A Phase I Study. <i>Tumori</i> , 2002, 88, 99-103.	1.1	4